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Available online 11 February 2016The Genea050 human embryonic stem cell line was derived from a donated, fully commercially consented ART
blastocyst, carrying a deletion in 4q35with only 5 D4Z4 repeats by PGD linkage analysis, indicative of FSHD1. Fol-
lowing ICM outgrowth on inactivated human feeders, karyotype was conﬁrmed as 46, XY and STR analysis dem-
onstrated amaleAllele pattern. The hESC line had pluripotent cellmorphology, 92% of cells expressedNanog, 97%
Oct4, 79% Tra1-60 and 99% SSEA4, gave a Pluritest Pluripotency score of 25.45, Novelty of 1.45 demonstrated Al-
kaline Phosphatase activity and tri-lineage teratoma formation. The cell line was negative for Mycoplasma and
visible contamination.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Resource tableDame of stem cell line
KGenea050 — FSHD1 affected (Alternate ID:
SIVF050)Sestitution Genea Biocells
Person who created resource Omar Chamiontact person and email biljana.dumevska@geneabiocells.com
Date archived/stock date August, 2009rigin Human embryos
Stpe of resource Derived human embryonic stem cell lineb-type FSHD1 affected human pluripotent cell line
Siey marker expression Nanog, Oct4, Tra1-60, and SSEA4uthentication Identity and purity of cell line conﬁrmed
(Figs. 1–2 and Tables 1–2 below)nk to related literature (direct
URL links and full references)(Laurent et al., 2011)
http://www.ncbi.nlm.nih.gov/pubmed/
?term=21211785formation in public databases National Institutes of Health registered, NIH:
NIHhESC-12-0184
UK Stem Cell Bank registered, UKSCB:
SCSC14-54
SNP Data Gene Expression Omnibus accession
number, GEO: GSM638452thical Approval Obtained from the Genea Ethics Committee
on 13 September 2005 under the Australian
National Health and Medical Research Council
(NHMRC) licence 309710(B. Dumevska).
. This is an open access article underResource detailstheate of derivationCC BY-NC-ND license (hJuly 2009
aryotype 46, XY
x Male
luripotent YES — by Nanog, Oct4, Tra1-60, and SSEA4 staining,
Pluritest, Alkaline Phosphatase and teratoma
isease status deletion in 4q35, 5 D4Z4 repeats — Facioscapulohumeral
muscular dystrophy 1 (FSHD1) affected, OMIM: 158900
erility The cell line is tested and found negative forMycoplasma
and any visible contamination
bling lines available YES — GENEA049 (FSHD1 affected — XX, NIH:
NIHhESC-12-0183, UKSCB: SCSC14-54)Materials and methods
Cell line derivation
20%KSRmedium (Amit et al., 2000)was conditioned by culturewith
high density mitotically inactivated feeders (72,000 cells/cm2) for 24 h
@ 37degrees 5% CO2 5% O2. The medium is collected every second day
for a period of 2 weeks. Medium from the 2 weeks is combined. The
fresh embryo was plated whole onto mitomycin C inactivated human
feeders (Detroit 551 HFF — 90,000/well in 4-well) in hESC conditioned
20% KSR medium with 20 ng/ml FGF added fresh. CGH karyotyping
and STR proﬁling were performed at the ﬁrst cryobanking step from
ICM outgrowths maintained on feeders. Alkaline Phosphatase staining
and teratoma formation were performed from feeders. Cells were then
enzymatically passaged as single cells in M2 pluripotent cell mainte-
nance medium (Genea Biocells) and CGH/karyotyping repeated,ttp://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
CGH analysis summary; Genea050 (passage 8, 3 enzymatic) reporting a male cell line and
no abnormalities detected.
CGH summary
Sample name Genea 50_p8_TE3
Date reported 1st May 2013
Hybridisation balance Balanced hybridization was observed for all
chromosomes, relative to reference DNA
Copy number change No copy number changes N400 kb were detected
Interpretation Male cell line — no abnormalities detected
Fig. 1. Morphology and karyotype of Genea050. A) Brightﬁeld (passage 1) growing on
human inactivated feeders. B) Alkaline Phosphatase activity (passage 6) on human
inactivated feeders. C) Karyotypic analysis (passage 5, 1 enzymatic) showing 46, XY
normal, male karyotype.
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testing performed.
Genetic analysis
1. Karyotyping: Passage 5; for enrichment of metaphase cells, cellular
outgrowths were incubated with either 0.22 ng/ml colcemid
(Invitrogen) and 37.5 g/ml BrdU (Sigma) for 17–19 h or 5 ng/ml
colcemid for 2.5 h. Single cells were subsequently obtained using
Non-Enzymatic Cell Dissociation Solution (Sigma) and transferred
to Sydney IVF's (now Genea) diagnostic cytogenetics laboratory
for preparation of metaphase spreads and cytogenetic analysis by
G-banding. A minimum of 15 metaphase cells were examined, of
which a full karyotype or chromosome counts were performed for
5 and 10 of the metaphases respectively.
2. Comparative Genomic Hybridisation (CGH) based chromosomal analy-
sis: Passage 8; CGH was used to screen targeted regions of the
genome for gains and losses associated with chromosomal imbal-
ances such as aneuploidy, deletions and duplications. CGH was per-
formed using SurePrint G3 microarrays (8x 60K format) which
were scanned with the Agilent Scanner C and analysed usingGenomic Workbench Standard Edition 5.0 software (Agilent
Technologies).
3. DNA Proﬁling: Passage 2; DNA ‘ﬁngerprinting’ was performed using
the AmpFLSTR Identiﬁler PCR Ampliﬁcation Kit (Applied Biosystems
#4322288) to provide permanent genetic identiﬁcation of the
cell lines. https://www.thermoﬁsher.com/order/catalog/product/
4322288
Pluripotency assessment
1. Immunoﬂuorescence: Passage 7 (5 on feeders, 2 enzymatic); cells
were ﬁxed with formalin and stained with Nanog #560483 1:200;
Oct4 #560217 1:150: Tra1-60 #560121 1:150; and SSEA4 #560308
1:200 (all BD Pharmingen). Images were acquired with an IN Cell
Analyser 6000 and quantiﬁed using In Cell Developer Software (GE).
2. Pluritest: Passage 8 (5 on feeders, 3 enzymatic); RNA was collected
and subjected to a Pluritest, a bioinformatic assay of pluripotency in
human cells based on gene expression proﬁles (Müller et al., 2012).
3. Alkaline Phosphatase: Passage 6; Genea050 grown on feeders was
stained as per manufacturer's protocol using the Merck Millipore
Alkaline Phosphatase Detection Kit (SCR004).
4. Teratoma formation: Passage 5; Genea050 was injected intramuscu-
larly to immuno-deﬁcient mice and resultant teratomas excised,
ﬁxed, sectioned and stained for assessment of tissues from each of
the embryonic germ layers.
Sterility testing
1. Mycoplasma: Passage 12; testing was performed at the Victorian
Infectious Diseases Reference Laboratory using Mycoplasma Genus
PCR.
2. Microbial contamination: testing was performed in conjunction with
our QC measures. Cells were thawed and cultured in 7 ml antibiotic
free medium (Genea Biocells M2 medium) for 2–3 days at 37 °C. A
clear solution at ~48–72 h indicated lack of bacterial, fungal or
yeast contamination. Clarity of the solution was assessed by Cell
Production Team.
Veriﬁcation and authentication
Ethics/consents
Ethics approval for the project (‘Derivation of human embryonic
stem cells from embryos identiﬁed through pre-implantation genetic
diagnosis to be affected by known genetic conditions’) was obtained
from the Genea Ethics Committee on 13 September 2005. Excess ART
embryoswere fully consented for stem cell derivation by all responsible
people through an informed consent process (signed de-identiﬁed con-
sent form can be provided upon request). Donors have received no pay-
ment or ﬁnancial beneﬁts for their donation. Genea050 has been
derived from a donated, fully commercially consented embryo, original-
ly created by assisted reproduction technology (ART) for the purpose of
procreation. The embryo was identiﬁed through pre-implantation ge-
netic diagnosis to be affected by a genetic mutation and was declared
Table 2
STR proﬁle; Genea050 (passage 2) demonstrating male Allele pattern.
D8S1179 D21S11 D7S820 CSF1PO D3S1358 TH01 D13S317 D16S539 D2S1338 D19S433 vWA TPOX D18S51 D5S818 FGA
SIVF050p2 13 28,30 8,11 10,11 15,17 6,8 11 11 20,25 14,15 17,18 9,11 11,15 11 21,22
505B. Dumevska et al. / Stem Cell Research 16 (2016) 503–506excess to reproductive needs. Derivation was performed under
Australian National Health and Medical Research Council (NHMRC)
licence 309710. This licence was issued to GENEA on 7 May 2007.
More information about the licence can be obtained from the NHMRC
webpage at http://www.nhmrc.gov.au/health-ethics/human-embryos-
and-cloning/database-licences-authorising-use-excess-art-embryos.PGD analysis conclusion
Mutation; deletion is 4q35 in the D4Z4 DNA region. Family tree;
Father; b inherited from his Mother. Fragment size observed in patient
(father) was 22.6 kb using p13E-11 DNA probe (Upadhyaya et al.,
1997). Number of D4Z4 repeats calculated from Southern Blot is 5.
Facio-scapulo-humeral-muscular Dystrophy 1 (FSHD1) affected.Morphology
The derived stem cell line, Genea050, morphologically displays ad-
herent monolayer of compact cells in well-deﬁned colonies with high
nuclear to cytoplasmic ratio and prominent nucleoli (Fig. 1A/B).Fig. 2. Pluripotency validation of Genea050. A) Immunoﬂuorescent staining (10×) of pluripoten
enzymatic). B) Quantitation of expression of pluripotent markers. C) Pluritest Pluripotency (le
D) Tri-lineage teratoma formation (passage 5) with (left) gastrointestinal epithelium (middle)Genetic analysis
The cell line has been karyotyped (Fig. 1C, Supplementary Fig. 1) and
tested by CGH (Table 1, Supplementary Fig. 2), which demonstrated 46,
XY karyotype, consistent with original derivation and pre-implantation
genetic diagnosis (PGD). Analysis of STRmarkers showed Allele pattern
consistent with male genotype (Table 2, Supplementary Fig. 3).
Pluripotency
GENEA050 is pluripotent by;
1. Alkaline Phosphatase stain positivity (Fig. 1B)
2. Immunoﬂuorescence with 92% Nanog positive, 97% Oct4 positive,
79% Tra1-60 positive and 99% SSEA4 positive (Fig. 2A, quantiﬁed in
Fig. 2B).
3. Pluritest with a Pluripotency score of 25.45 and Novelty score of 1.45
(Fig. 2C).
4. Teratoma formation which contained tissues derived from each of
the embryonic germ layers: endoderm, mesoderm, and ectoderm
(Fig. 2D).t cellmarkers SSEA4 (green), Nanog (red), Oct3/4 (green) and Tra1/60 (red), (passage 7, 2
ft) and Novelty (right) scores with Genea050 (passage 8, 3 enzymatic) outlined in black.
, cartilage, smooth muscle (right) and primitive neuroglia.
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The cell line is tested and found negative for Mycoplasma and any
visible contamination (Supplementary Fig. 4).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2016.02.023.
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